
MNMD • NASDAQ
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold MNMD in your mock portfolio yet.
Mind Medicine (MindMed) remains loss-making, as reflected by its negative EPS and PE ratio. The current earnings profile suggests the business is still in an investment and development phase with no clear path to near‑term profitability implied by the data provided.
The stock has rallied sharply in the last month, yet technical indicators show a mixed picture. Price is well above the 200‑day moving average, but the RSI is below 40, suggesting the recent move may be consolidating or losing momentum rather than entering a strong overbought trend.
Alternative data suggest weakening or stagnant engagement around the company. Web traffic is modest, job postings have dropped to zero, and social media followership is flat to slightly declining, which together point to softening growth signals and limited marketing or expansion activity.
Despite a strong price move over the past month and a favorable position relative to the 200‑day moving average, Mind Medicine (MindMed) remains a loss‑making company with weak profitability and deteriorating alternative data signals. The combination of negative earnings, no visible hiring, and softening online and social engagement tilts the overall outlook more toward risk than opportunity at current levels.



Mind Medicine (MindMed) Inc. (MNMD) Q3 2025 Earnings Call Transcript

MindMed to Participate in Upcoming Investor Conferences
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: